BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 33275673)

  • 1. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
    Patnaik MM; Lasho T
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Patnaik MM; Lasho TL
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
    Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
    Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of MDS/MPN overlap syndromes.
    Hunter AM; Padron E
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic/myeloproliferative neoplasms.
    Hyjek E; Vardiman JW
    Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
    Kuendgen A; Kasprzak A; Germing U
    Front Oncol; 2021; 11():778741. PubMed ID: 34869027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I diagnose and treat chronic myelomonocytic leukemia.
    Patnaik MM
    Haematologica; 2022 Jul; 107(7):1503-1517. PubMed ID: 35236051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.
    Gerke MB; Christodoulou I; Karantanos T
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.
    Coston T; Pophali P; Vallapureddy R; Lasho TL; Finke CM; Ketterling RP; Carr R; Binder M; Mangaonkar AA; Gangat N; Al-Kali A; Litzow M; Zblewski D; Pardanani A; Tefferi A; Patnaik MM
    Am J Hematol; 2019 Jul; 94(7):767-779. PubMed ID: 30964202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
    Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Clara JA; Sallman DA; Padron E
    Cancer Biol Med; 2016 Sep; 13(3):360-372. PubMed ID: 27807503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
    Talati C; Padron E
    Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
    Carr RM; Patnaik MM
    Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
    Patnaik MM; Tefferi A
    Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?
    Itzykson R; Fenaux P; Solary E
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):387-400. PubMed ID: 24507815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes - Advances in treatment.
    McCullough KB; Patnaik MM
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101130. PubMed ID: 32460984
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Linder K; Iragavarapu C; Liu D
    Biomark Res; 2017; 5():33. PubMed ID: 29225884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.